September 13, 2022 — Prestige Medical Imaging (“PMI”) announced that it has completed acquisitions of XRV Healthcare and MedServ Plus. The additions of XRV Healthcare and MedServ Plus to the PMI business platform bring together three of the most prominent dealers in the medical imaging industry, solidifying the combined entity as the largest independent radiology service and solutions provider in the Eastern United States.
“We couldn’t be happier to have two incredible organizations in XRV Healthcare and MedServ Plus joining the PMI family,” said Bill Haussmann, Chief Executive Officer of Prestige Medical Imaging. “Our three companies present seamless fits both operationally and culturally, so we’re really excited for our employees and for our customers. The future is now for PMI.”
XRV Healthcare, a 20-year industry stalwart from Springfield, VA, bridges PMI’s comprehensive customer coverage area between the Northeast and Southeast. XRV Healthcare, like MedServ Plus, complements PMI’s existing sales and service organizations in a previously underdeveloped geographic segment. Bud Mori, Chief Executive Officer of XRV Healthcare, said of the deal, “We’ve long respected PMI and MedServ as leaders in the industry. To now be one organization with them is truly exciting for everyone here at XRV Healthcare.”
MedServ Plus—with offices in Beaver Falls, PA, and East Palestine, OH—bolsters PMI’s industry stronghold in the Great Lakes region with 19 years of expertise. MedServ Plus services and sells a broad suite of equipment modalities within PMI’s existing customer segments. Craig McCowin, President of MedServ Plus, commented, “We can’t wait to hit the ground running with PMI. It has always been important for us to retain our family values as we grow as an organization, and we’re doing just that in joining PMI. I’m looking forward to taking our companies to the next level of growth together.”
Prestige Medical Imaging and partner Atlantic Street Capital are actively seeking additional acquisitions to broaden PMI’s geographic footprint and enhance its suite of product offerings.
For more information: www.prestigemedicalimaging.com
March 24, 2023 
![A supply problem with Pluvicto [177Lu-vipivotide tetraxetan; Novartis], the radiopharmaceutical used to treat metastatic prostate cancer, has led to shortages resulting in a delay of 3 months or longer for new patients](/sites/default/files/styles/feed_medium/public/Screen%20Shot%202023-03-16%20at%201.46.39%20PM.png?itok=a2-uUeQz)